Sinphar Pharmaceutical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,371	3,151	2,963	2,857	2,434
Revenue Growth (YoY)	7.00%	6.33%	3.72%	17.39%	1.89%
Cost of Revenue	1,914	1,910	1,869	1,764	1,545
Gross Profit	1,457	1,240	1,094	1,093	888.71
Selling, General & Admin	894.67	791.65	670.93	621.34	557.06
Research & Development	145.37	151.36	132.58	272.16	511.88
Operating Expenses	1,040	943.15	805.19	893.97	1,071
Operating Income	416.86	297.16	288.74	198.63	-182.77
Interest Expense	-33.85	-36.77	-33.71	-27.81	-24.8
Interest & Investment Income	12.61	16.84	12.31	5.78	3.68
Currency Exchange Gain (Loss)	-	13.43	3.79	21.31	-6.96
Other Non Operating Income (Expenses)	5.9	18.93	29.46	47.96	27.82
EBT Excluding Unusual Items	401.52	309.58	300.58	245.86	-183.03
Gain (Loss) on Sale of Assets	-	-2.48	5.13	-0.81	-1.5
Pretax Income	401.52	307.1	305.71	245.05	-184.53
Income Tax Expense	47.25	21.88	-51.07	80.87	20.43
Earnings From Continuing Operations	354.27	285.22	356.78	164.17	-204.96
Minority Interest in Earnings	11.48	19.49	18.39	60.47	166.82
Net Income	365.75	304.71	375.17	224.64	-38.14
Net Income to Common	365.75	304.71	375.17	224.64	-38.14
Net Income Growth	20.03%	-18.78%	67.01%	-	-
Shares Outstanding (Basic)	190	190	190	190	190
Shares Outstanding (Diluted)	190	191	191	191	190
Shares Change (YoY)	-0.04%	0.02%	-0.00%	0.17%	-
EPS (Basic)	1.92	1.60	1.97	1.18	-0.20
EPS (Diluted)	1.92	1.60	1.97	1.18	-0.20
EPS Growth	20.00%	-18.84%	66.91%	-	-
Free Cash Flow	389.95	353.08	0.86	283.82	-10.64
Free Cash Flow Per Share	2.05	1.85	0.01	1.49	-0.06
Dividend Per Share	-	0.952	0.882	0.882	0.176
Dividend Growth	-	7.99%	0.01%	399.89%	-
Gross Margin	43.21%	39.37%	36.92%	38.25%	36.52%
Operating Margin	12.37%	9.43%	9.74%	6.95%	-7.51%
Profit Margin	10.85%	9.67%	12.66%	7.86%	-1.57%
Free Cash Flow Margin	11.57%	11.21%	0.03%	9.93%	-0.44%
EBITDA	671.19	539.99	518.14	446.69	63.93
EBITDA Margin	19.91%	17.14%	17.49%	15.64%	2.63%
D&A For EBITDA	254.33	242.83	229.4	248.06	246.7
EBIT	416.86	297.16	288.74	198.63	-182.77
EBIT Margin	12.37%	9.43%	9.74%	6.95%	-7.51%
Effective Tax Rate	11.77%	7.13%	-	33.00%	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.